15 Stocks Moving In Monday's After-Hours Session

Gainers

• Omeros (NASDAQ: OMER) shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.
• Fate Therapeutics (NASDAQ: FATE) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
• Livongo Health (NASDAQ: LVGO) shares are trading higher after the company reported better-than-expected Q4 sales results. The company also issued Q1 and FY20 sales guidance above estimates.
• GenMark Diagnostics (NASDAQ: GNMK) shares are trading higher after the company reported Q4 earnings results.
• GreenSky (NASDAQ: GSKY) shares are trading higher after the company reported Q4 earnings.
• Verra Mobility (NASDAQ: VRRM) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
• Boingo Wireless (NASDAQ: WIFI) shares are trading higher after the company reported Q4 earnings.
• Impinj (NYSE: PI) shares are trading higher after the company reported Q4 EPS up from the same quarter last year and better-than-expected Q4 sales results.

Losers

• Karyopharm Therapeutics (NASDAQ: KPTI) shares are trading lower after the company announced a proposed public offering of common stock of $150 million.
• Tilray (NASDAQ: TLRY) shares are trading lower after the company reported worse-than-expected Q4 sales results.
• Realty Income (NYSE: O) shares are trading lower after the company announced the closing of a 9 million share common stock offering.
• EHealth (NASDAQ: EHTH) shares are trading lower after the company announced a 1.5 million share common stock offering.
• BeiGene (NASDAQ: BGNE) shares are trading lower after the company reported Q4 EPS and sales were down from the same quarter last year.
• AppFolio (NASDAQ: APPF) shares are trading lower after the company issued FY20 sales guidance below estimates.
• Visa (NYSE: V) shares are trading lower after the company reported it sees Q2 roughly 2.5-3.5% lower than prior outlook. The company also said it can't accurately forecast the growth trend for the rest of Q2 and 2020 due to the coronavirus outbreak.